European Medicines Agency has started the review of third- and fourth-generation combined oral contraceptives
Due to a recent initiative to reduce the use of third- and fourth-generation combined oral contraceptives, the European Medicines Agency has been requested by France to review the benefits risks ratio of third- and fourth-generation (so called "newer" combined oral contraceptives) combined oral contraceptives. The review of benefits risks ratio is being carried out in order to determine whether there is a need to restrict the use of these medicinal products to women who cannot take other combined oral contraceptives. The EMA’s Pharmacovigilance Assessment Committee (PRAC) will be reviewing whether the currently available product information on combined oral contraceptives provides the best information possible for patients and doctors to take appropriate healthcare decisions. New information about the review by the PRAC will be available by the end of next week.
You may find further details in the continuation of this information.